BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 22487818)

  • 1. [Correlation between RARbeta gene promoter methylation and P53 gene mutations in non-small cell lung cancer].
    Tan C; Jin YT; Xu HY; Zhang CY; Zhang H; Zhang WM; Chen CM; Sun XY
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2012 Apr; 29(2):131-6. PubMed ID: 22487818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation with p53 mutation occurrence in non-small cell lung cancer with different histology, gender, and smoking status.
    Wu JY; Wang J; Lai JC; Cheng YW; Yeh KT; Wu TC; Chen CY; Lee H
    Ann Surg Oncol; 2008 Nov; 15(11):3272-7. PubMed ID: 18712569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant promoter methylation in Chinese patients with non-small cell lung cancer: patterns in primary tumors and potential diagnostic application in bronchoalevolar lavage.
    Chan EC; Lam SY; Tsang KW; Lam B; Ho JC; Fu KH; Lam WK; Kwong YL
    Clin Cancer Res; 2002 Dec; 8(12):3741-6. PubMed ID: 12473584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer.
    Huang C; Taki T; Adachi M; Konishi T; Higashiyama M; Miyake M
    Oncogene; 1998 May; 16(19):2469-77. PubMed ID: 9627113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.
    Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H
    Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of CYP1A1 MSPI polymorphism on the relationship between TP53 mutation and CDKN2A hypermethylation in non-small cell lung cancer.
    Tan C; Xu HY; Zhang CY; Zhang H; Chen CM; Zhang WM; Sun XY; Jin YT
    Arch Med Res; 2011 Nov; 42(8):669-76. PubMed ID: 22154617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. O(6)-Methylguanine-DNA methyltransferase promoter hypermethylation shifts the p53 mutational spectrum in non-small cell lung cancer.
    Wolf P; Hu YC; Doffek K; Sidransky D; Ahrendt SA
    Cancer Res; 2001 Nov; 61(22):8113-7. PubMed ID: 11719438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer.
    Kim H; Kwon YM; Kim JS; Lee H; Park JH; Shim YM; Han J; Park J; Kim DH
    J Clin Oncol; 2004 Jun; 22(12):2363-70. PubMed ID: 15197197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RARβ Promoter Methylation as an Epigenetic Mechanism of Gene Silencing in Non-small Cell Lung Cancer.
    Dutkowska A; Antczak A; Pastuszak-Lewandoska D; Migdalska-Sek M; Czarnecka KH; Górski P; Kordiak J; Nawrot E; Brzeziańska-Lasota E
    Adv Exp Med Biol; 2016; 878():29-38. PubMed ID: 26453065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promoter methylation of DAP-kinase: association with advanced stage in non-small cell lung cancer.
    Kim DH; Nelson HH; Wiencke JK; Christiani DC; Wain JC; Mark EJ; Kelsey KT
    Oncogene; 2001 Mar; 20(14):1765-70. PubMed ID: 11313923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exon 8 mutation of p53 gene associated with nodal metastasis in non-small-cell lung cancer.
    Lee LN; Shew JY; Sheu JC; Lee YC; Lee WC; Fang MT; Chang HF; Yu CJ; Yang PC; Luh KT
    Am J Respir Crit Care Med; 1994 Dec; 150(6 Pt 1):1667-71. PubMed ID: 7952630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant promoter methylation of multiple genes in non-small cell lung cancers.
    Zöchbauer-Müller S; Fong KM; Virmani AK; Geradts J; Gazdar AF; Minna JD
    Cancer Res; 2001 Jan; 61(1):249-55. PubMed ID: 11196170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women.
    Gealy R; Zhang L; Siegfried JM; Luketich JD; Keohavong P
    Cancer Epidemiol Biomarkers Prev; 1999 Apr; 8(4 Pt 1):297-302. PubMed ID: 10207632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.
    Hashimoto T; Tokuchi Y; Hayashi M; Kobayashi Y; Nishida K; Hayashi S; Ishikawa Y; Tsuchiya S; Nakagawa K; Hayashi J; Tsuchiya E
    Cancer Res; 1999 Nov; 59(21):5572-7. PubMed ID: 10554037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can aberrant promoter hypermethylation of CpG islands predict the clinical outcome of non-small cell lung cancer after curative resection?
    Kim YT; Lee SH; Sung SW; Kim JH
    Ann Thorac Surg; 2005 Apr; 79(4):1180-8; discussion 1180-8. PubMed ID: 15797047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypermethylation of FHIT as a prognostic marker in nonsmall cell lung carcinoma.
    Maruyama R; Sugio K; Yoshino I; Maehara Y; Gazdar AF
    Cancer; 2004 Apr; 100(7):1472-7. PubMed ID: 15042681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis.
    de Anta JM; Jassem E; Rosell R; Martínez-Roca M; Jassem J; Martínez-López E; Monzó M; Sánchez-Hernández JJ; Moreno I; Sánchez-Céspedes M
    Oncogene; 1997 Dec; 15(24):2951-8. PubMed ID: 9416838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group.
    Chiba I; Takahashi T; Nau MM; D'Amico D; Curiel DT; Mitsudomi T; Buchhagen DL; Carbone D; Piantadosi S; Koga H
    Oncogene; 1990 Oct; 5(10):1603-10. PubMed ID: 1979160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of occult tumor cells in peripheral blood from patients with small cell lung cancer by promoter methylation and silencing of the retinoic acid receptor-beta.
    Oshita F; Sekiyama A; Suzuki R; Ikehara M; Yamada K; Saito H; Noda K; Miyagi Y
    Oncol Rep; 2003; 10(1):105-8. PubMed ID: 12469153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evaluation of the prognostic significance of P53 mutation in patients with non-small cell lung cancer].
    Jassem E; Rosell R; Jassem J; Monzo M; Kobierska G; Badzio A; Roszkiewicz A; Skokowski J; Szulc A
    Pneumonol Alergol Pol; 1998; 66(5-6):290-6. PubMed ID: 9857649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.